Broncus FY26 H1 net loss widens 4.3% to US$ 8.13 million; revenue more than doubled to US$ 3.29 million

• Broncus posted revenue of US$3.29 million, more than doubled from a year earlier, while IFRS net loss widened 4.3% to US$8.13 million.
• Gross profit rose 83.8% to US$2.23 million; gross margin fell 5.6 percentage points to 67.9%.
• Non-IFRS adjusted net loss widened 14.7% to US$7.98 million; share-award expense dropped 82.3% to US$148,000.
• Cash and bank balances slid to US$99.3 million from Dec. 31, 2025, partly due to operating spend and Valgen preferred-share purchases.
• BroncAblate reached about 30 provinces/cities in China with over 300 cumulative uses, while BroncTarget’s confirmatory trial enrolled 124 subjects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Broncus Holding Corporation published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12302268), on August 27, 2026, and is solely responsible for the information contained therein.